Candrika D Khairani
Overview
Explore the profile of Candrika D Khairani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
52
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Piazza G, Hurwitz S, Campia U, Bikdeli B, Lou J, Khairani C, et al.
Thromb Res
. 2023 May;
227:1-7.
PMID: 37182298
Background: Despite widely available risk stratification tools, safe and effective anticoagulants, and guideline recommendations, anticoagulation for stroke prevention in atrial fibrillation (AF) is under-prescribed in ambulatory patients. To assess the...
12.
Bikdeli B, Muriel A, Wang Y, Piazza G, Khairani C, Rosovsky R, et al.
Semin Thromb Hemost
. 2023 Mar;
49(7):725-735.
PMID: 36868268
Sex-specific factors are implicated in pulmonary embolism (PE) presentation in young patients, as indicated by increased risk in pregnancy. Whether sex differences exist in PE presentation, comorbidities, and symptomatology in...
13.
Bikdeli B, Lo Y, Khairani C, Bejjani A, Jimenez D, Barco S, et al.
Thromb Haemost
. 2023 Feb;
123(6):649-662.
PMID: 36809777
Background: Contemporary pulmonary embolism (PE) research, in many cases, relies on data from electronic health records (EHRs) and administrative databases that use International Classification of Diseases (ICD) codes. Natural language...
14.
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, et al.
J Am Coll Cardiol
. 2022 Nov;
81(1):16-30.
PMID: 36328154
Background: The efficacy and safety of direct oral anticoagulants (DOACs) for patients with thrombotic antiphospholipid syndrome remain controversial. Objectives: The authors performed a systematic review and meta-analysis of randomized controlled...
15.
Bejjani A, Khairani C, Campia U, Piazza G
J Clin Med
. 2022 Oct;
11(20).
PMID: 36294450
Pulmonary embolism (PE) continues to represent a significant health care burden and its incidence is steadily increasing worldwide. Constantly evolving therapeutic options and the rarity of randomized controlled trial data...
16.
Leiva O, Campia U, Snyder J, Barns B, Rizzo S, Khairani C, et al.
Res Pract Thromb Haemost
. 2022 Aug;
6(5):e12752.
PMID: 35979196
Background: Both coronavirus disease-2019 (COVID-19) and myeloproliferative neoplasms (MPNs) are associated with systemic inflammation and risk of thrombosis. Risk of thrombosis in patients with COVID with and without MPNs has...
17.
Bejjani A, Khairani C, Piazza G
Semin Thromb Hemost
. 2022 Jul;
49(8):797-808.
PMID: 35777420
Right ventricular (RV) failure is a critical cause of morbidity and mortality in patients presenting with pulmonary embolism (PE). The presentation of RV failure is based on the combination of...
18.
Bikdeli B, Piazza G, Jimenez D, Muriel A, Wang Y, Khairani C, et al.
Thromb Res
. 2022 May;
214:122-131.
PMID: 35537232
Background: Sex is an important factor associated with pulmonary embolism (PE) disease presentation and outcomes, which may be related to pathobiological, social, and treatment-based differences. We are seeking to illuminate...
19.
Bikdeli B, Khairani C, Barns B, Rosovsky R, Jimenez D, Monreal M, et al.
Contemp Clin Trials
. 2022 Feb;
115:106714.
PMID: 35202841
No abstract available.
20.
Bikdeli B, Hogan H, Morrison R, Fanikos J, Campia U, Barns B, et al.
Thromb Haemost
. 2021 Sep;
122(6):1061-1070.
PMID: 34530470
Patients with acute venous thromboembolism (VTE) in the setting of transient provoking factors are typically treated with short-term anticoagulation. However, the risk of recurrence may be increased in the presence...